美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Novo Nordisk A/S B Shares ADRhedged

23.43

-0.5279-2.20%

盤後：23.950.5279+2.25%18:25 EDT

成交量：242

成交額：5,662

市值：374.82萬

市盈率：- -

高：23.43

開：23.95

低：23.43

收：23.95

52周最高：34.36

52周最低：19.00

股本：16.00萬

流通股本：16.00萬

量比：0.19

換手率：0.15%

股息：1.70

股息率：7.24%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

國產藥加速追趕減重明星賽道進入「群雄逐鹿」時代

諾和諾德首席執行官：相較於注射劑，口服版 Wegovy 的市場需求之高，讓我們愈發感到意外。

諾和諾德股價下跌6.8%，觸及盤中低點。

諾和諾德：目前美國市場索馬魯肽注射劑Wegovy的價格走勢與我們年初啓動定價時一致。

諾和諾德首席財務官表示：我們推進全公司轉型以實現80億丹麥克朗成本節約目標的進度，目前已超前於計劃。

諾和諾德股價跌勢擴大，目前跌幅已超5%，年初至今累計下跌10%。

諾和諾德(NVO.US)首席執行官：我們將在資本市場日上詳細介紹如何加速早期資產和早期科學的推進。

諾和諾德首席執行官：進行合併或收購的企業目前都陷入了某種困境，它們已經無法再開展創新了。

諾和諾德CEO力挺Wegovy口服片劑，售價下行拖累銷售，公司股價走低

环球市场播报

諾和諾德首席執行官：目前無意開展重大轉型式收購交易。

諾和諾德首席執行官：公司不會討論進一步降低藥品折扣。

諾和諾德Q2業績超預期、上調全年指引卻難掩隱憂

諾和諾德CEO業績展望上調，然研發管線隱憂未散，遭投資者質詢

諾和諾德首席財務官：我們目前沒有任何在未來推行成本削減的計劃。

諾和諾德首席執行官：減肥藥Wegovy口服劑型很快將在德國上市。

諾和諾德首席財務官：我們認為我們的定價定位合理。

諾和諾德首席財務官表示：目前Wegovy口服片劑主要由患者自費購買，受市場動態影響，未來價格大概率會出現調整。

諾和諾德首席執行官：CagriSema仍是一款藥效極強的藥物。

諾和諾德首席執行官表示：我們堅信，我們擁有極為充裕的研發管線，且研發能力十分出色。

諾和諾德首席執行官：Wegovy口服片已佔據口服肥胖症藥物市場約90%的份額.

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/NVOH/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVOH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","market":"US","secType":"STK","nameCN":"Novo Nordisk A/S B Shares ADRhedged","latestPrice":23.4261,"timestamp":1789156800000,"preClose":23.954,"halted":0,"volume":242,"hourTrading":{"tag":"盘后","latestPrice":23.954,"preClose":23.4261,"latestTime":"18:25 EDT","volume":52,"amount":1234.5988,"timestamp":1789165501424,"change":0.5279,"changeRate":0.022535,"amplitude":0},"delay":0,"changeRate":-0.022038072973198587,"floatShares":160001,"shares":160001,"eps":0,"marketStatus":"休市中","change":-0.5279,"latestTime":"09-11 16:00:00 EDT","open":23.954,"high":23.4261,"low":23.4261,"amount":5662,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":23.954,"nav":23.86567,"aum":3818531.06567,"dividendRate":0.072402,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.954,"preClose":23.4261,"latestTime":"18:25 EDT","volume":52,"amount":1234.5988,"timestamp":1789165501424,"change":0.5279,"changeRate":0.022535,"amplitude":0},"volumeRatio":0.19422107657683185,"impliedVol":0.2658,"impliedVolPercentile":0.6372},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","floatShares":160001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.19422107657683185,"shares":160001,"dividePrice":1.6961,"high":23.4261,"amplitude":0,"preClose":23.954,"low":23.4261,"week52Low":19,"pbRate":"--","week52High":34.36,"institutionHeld":0,"latestPrice":23.4261,"eps":0,"divideRate":0.072402,"volume":242,"delay":0,"ttmEps":0,"open":23.954,"prevYearClose":27.4362,"prevWeekClose":25.2595,"prevMonthClose":24.5859,"prevQuarterClose":26.0576,"fiveDayClose":25.6877,"twentyDayClose":25.2491,"sixtyDayClose":23.411},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"NVOH","amount":0.76666,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"NVOH","amount":0.27495,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"NVOH","amount":0.48798,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2025-09-16","symbol":"NVOH","amount":0.16566,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"Novo Nordisk A/S (B Shares) ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-23","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOH\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-16","recordDate":"2025-09-16","paymentDate":"2025-09-23","value":0.16566,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.48798,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.27495,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.76666,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOH\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657547441","title":"國產藥加速追趕 減重明星賽道進入「群雄逐鹿」時代","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547441","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657547441?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:07","pubTimestamp":1785935232,"startTime":"0","endTime":"0","summary":"新华财经上海8月5日电2026年，我国“体重管理年”三年行动进入收官之年。当前，全民体重管理意识和技能显著提升，健康生活方式更加普及，部分人群体重异常状况得到改善。体重管理催生了减重经济。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832808212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832808212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["RSPH","JDOC","NVOH","THNR","NVOX","NVOC","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657073541","title":"諾和諾德首席執行官：相較於注射劑，口服版 Wegovy 的市場需求之高，讓我們愈發感到意外。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657073541","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657073541?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 20:04","pubTimestamp":1785931485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","OZEM","PPH","NVOX","LU0154236417.USD","LU1093756168.USD","BK4599","NVO","LU1093756325.SGD","BK4585","BK4532","THNR","NVOH","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657490745","title":"諾和諾德股價下跌6.8%，觸及盤中低點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657490745","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657490745?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:43","pubTimestamp":1785930191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0154236417.USD","NVOX","THNR","BK4532","IE00BKVL7J92.USD","PPH","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","BK4585","OZEM","BK4588","LU1093756325.SGD","NVOH","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657003549","title":"諾和諾德：目前美國市場索馬魯肽注射劑Wegovy的價格走勢與我們年初啓動定價時一致。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657003549","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657003549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:42","pubTimestamp":1785930157,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","NVOH","OZEM","LU1093756325.SGD","NVOX","BK4532","LU0154236417.USD","BK4585","PPH","THNR","NVO","IE00BKVL7J92.USD","LU1093756168.USD","BK4588","BK4599","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657539549","title":"諾和諾德首席財務官表示：我們推進全公司轉型以實現80億丹麥克朗成本節約目標的進度，目前已超前於計劃。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657539549","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657539549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:23","pubTimestamp":1785929036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOX","OZEM","LU1093756325.SGD","NVOH","NVO","BK4007","BK4532","IE00BKVL7J92.USD","BK4588","IE00BZ1G4Q59.USD","PPH","THNR","BK4585","LU0154236417.USD","BK4599","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510014","title":"諾和諾德股價跌勢擴大，目前跌幅已超5%，年初至今累計下跌10%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510014?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:06","pubTimestamp":1785924365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["OZEM","LU0154236417.USD","NVO","THNR","IE00BKVL7J92.USD","BK4588","BK4585","BK4532","BK4007","LU1093756168.USD","PPH","BK4599","NVOH","NVOX","LU1093756325.SGD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657107295","title":"諾和諾德(NVO.US)首席執行官：我們將在資本市場日上詳細介紹如何加速早期資產和早期科學的推進。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657107295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657107295?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:03","pubTimestamp":1785924200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["OZEM","LU0154236417.USD","THNR","BK4585","BK4532","PPH","NVOH","BK4588","NVOX","LU1093756325.SGD","LU1093756168.USD","NVO","IE00BKVL7J92.USD","BK4007","BK4599","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510267","title":"諾和諾德首席執行官：進行合併或收購的企業目前都陷入了某種困境，它們已經無法再開展創新了。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510267","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510267?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:01","pubTimestamp":1785924082,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","BK4585","BK4007","OZEM","BK4599","THNR","LU0154236417.USD","PPH","NVOX","NVO","IE00BKVL7J92.USD","LU1093756168.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4588","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657551275","title":"諾和諾德CEO力挺Wegovy口服片劑，售價下行拖累銷售，公司股價走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2657551275","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657551275?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 17:02","pubTimestamp":1785920520,"startTime":"0","endTime":"0","summary":"投资者持续聚焦价格压力、业绩超预期的可持续性，以及 Wegovy 口服片剂能否成为足够强劲的增长引擎，扭转公司增长颓势。诺和诺德坦言，产品降价持续拖累销售收入。不过 CEO 迈克杜斯塔达尔表示，销量持续攀升叠加 Wegovy 口服片剂初期销售表现，证明当前经营策略行之有效。周三交易开盘前，诺和诺德丹麦本土个股年内累计下跌约 5%；尽管 Wegovy 口服片剂上市后股价有所修复，但较 2024 年年中高点仍大跌近 70%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-05/doc-inimhawm4660383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4585","NVOH","LU1093756168.USD","BK4588","NVO","THNR","BK4532","BK4599","PPH","OZEM","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU0154236417.USD","IE00BKVL7J92.USD","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511799","title":"諾和諾德首席執行官：目前無意開展重大轉型式收購交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511799","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511799?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:30","pubTimestamp":1785918656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ1G4Q59.USD","NVO","NVOH","BK4588","NVOX","IE00BKVL7J92.USD","LU1093756325.SGD","PPH","OZEM","THNR","BK4007","BK4585","BK4599","LU1093756168.USD","BK4532","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511459","title":"諾和諾德首席執行官：公司不會討論進一步降低藥品折扣。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511459","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511459?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:26","pubTimestamp":1785918369,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","OZEM","PPH","NVOX","LU0154236417.USD","LU1093756168.USD","BK4599","NVO","LU1093756325.SGD","BK4585","BK4532","THNR","NVOH","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657519148","title":"諾和諾德Q2業績超預期、上調全年指引卻難掩隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2657519148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657519148?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:49","pubTimestamp":1785916176,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德Q2业绩超预期、上调全年指引却难掩隐忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0154236417.USD","NVOX","THNR","BK4532","IE00BKVL7J92.USD","PPH","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","BK4585","OZEM","BK4588","LU1093756325.SGD","NVOH","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2657403515","title":"諾和諾德CEO業績展望上調，然研發管線隱憂未散，遭投資者質詢","url":"https://stock-news.laohu8.com/highlight/detail?id=2657403515","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657403515?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:00","pubTimestamp":1785913213,"startTime":"0","endTime":"0","summary":"“Cagrisema再次令人失望，这可能凸显了诺和诺德面临的最大战略问题。”他表示，这些令人失望的结果将促使诺和诺德加快研发步伐并更加积极地寻求合作机会，而非变得更加谨慎。“这将诺和诺德的研发管线及其稳健性推到了聚光灯下，”AL Sydbank在致客户的报告中表示，并补充道，尽管诺和诺德的业绩本应让投资者松一口气，但这些数据和减值准备却打击了市场情绪。他表示，当务之急是扩大研发管线，同时保持生产效率的纪律性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4S4420LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4599","IE00BKVL7J92.USD","OZEM","THNR","BK4585","BK4588","BK4007","NVOH","PPH","LU0154236417.USD","NVO","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVOX","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657251339","title":"諾和諾德首席財務官：我們目前沒有任何在未來推行成本削減的計劃。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657251339","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657251339?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:28","pubTimestamp":1785911326,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","THNR","BK4532","BK4585","BK4007","LU0154236417.USD","LU1093756325.SGD","NVOX","OZEM","PPH","NVO","BK4599","NVOH","BK4588","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657151338","title":"諾和諾德首席執行官：減肥藥Wegovy口服劑型很快將在德國上市。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657151338","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657151338?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:23","pubTimestamp":1785911038,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","PPH","IE00BKVL7J92.USD","BK4585","OZEM","NVOH","LU1093756325.SGD","BK4532","LU0154236417.USD","BK4007","BK4599","IE00BZ1G4Q59.USD","NVO","LU1093756168.USD","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657187875","title":"諾和諾德首席財務官：我們認為我們的定價定位合理。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657187875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657187875?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:15","pubTimestamp":1785910546,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVO","IE00BZ1G4Q59.USD","THNR","BK4585","BK4007","OZEM","PPH","BK4532","LU1093756168.USD","NVOX","LU0154236417.USD","LU1093756325.SGD","BK4599","BK4588","IE00BKVL7J92.USD","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657518786","title":"諾和諾德首席財務官表示：目前Wegovy口服片劑主要由患者自費購買，受市場動態影響，未來價格大概率會出現調整。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657518786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657518786?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:15","pubTimestamp":1785910533,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","OZEM","PPH","NVOX","LU0154236417.USD","LU1093756168.USD","BK4599","NVO","LU1093756325.SGD","BK4585","BK4532","THNR","NVOH","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657518782","title":"諾和諾德首席執行官：CagriSema仍是一款藥效極強的藥物。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657518782","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657518782?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:14","pubTimestamp":1785910446,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1093756168.USD","NVOH","BK4599","BK4007","LU1093756325.SGD","BK4585","LU0154236417.USD","NVO","PPH","IE00BZ1G4Q59.USD","OZEM","BK4532","THNR","NVOX","IE00BKVL7J92.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657518282","title":"諾和諾德首席執行官表示：我們堅信，我們擁有極為充裕的研發管線，且研發能力十分出色。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657518282","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657518282?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:12","pubTimestamp":1785910332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0154236417.USD","NVOX","THNR","BK4532","IE00BKVL7J92.USD","PPH","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","BK4585","OZEM","BK4588","LU1093756325.SGD","NVOH","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657115518","title":"諾和諾德首席執行官：Wegovy口服片已佔據口服肥胖症藥物市場約90%的份額.","url":"https://stock-news.laohu8.com/highlight/detail?id=2657115518","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657115518?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:07","pubTimestamp":1785910062,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BKVL7J92.USD","BK4007","BK4585","NVOX","THNR","BK4532","LU1093756168.USD","PPH","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4599","NVO","BK4588","NVOH","OZEM","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}